U.S. Bioscience Inc., a developer of treatments for cancer andrelated diseases, has acquired exclusive rights to marketHexalen (altretamine) in Canada from Rhone-Poulenc Rorer.Hexalen, used to treat ovarian cancer, has been marketed inCanada by Rhone-Poulenc.

West Conshohocken, Pa.-based U.S. Bioscience began marketingHexalen in the United States in January. The company(AMEX:UBS) sublicensed the drug from Wyeth Laboratories Inc.,which had licensed it from Rhone-Poulenc.

(c) 1997 American Health Consultants. All rights reserved.